| Literature DB >> 26568366 |
Luo Jiang1, Rui Hou2, Ting-Ting Gong2, Qi-Jun Wu3.
Abstract
Epidemiological studies have provided controversial evidence of the association between dietary fat intake and endometrial cancer (EC) risk. To address this inconsistency, we conducted this dose-response meta-analysis by total dietary fat intake, based on epidemiological studies published up to the end of June 2015 identified from PubMed, EMBASE and Web of Science. Two authors (RH and Q-JW) independently performed the eligibility evaluation and data extraction. All differences were resolved by discussion with the third investigator (LJ). Random-effects models were used to estimate summary relative risks (RRs) and 95% confidence intervals (CIs). Overall, the search yielded 16 studies (6 cohort and 10 case-control studies) that involved a total of 7556 EC cases and 563,781 non-cases. The summary RR for EC for each 30 g/day increment intake was 0.98 (95%CI = 0.95-1.001; I(2) = 0%; n = 11) for total dietary fat. Non-significant results were observed in plant-based fat (summary RR = 1.05, 95%CI = 0.94-1.18; I(2) = 0%; n = 5) and animal-based fat (summary RR = 1.17, 95%CI = 0.92-1.36; I(2) = 85.0%; n = 6). Additionally, the null associations were observed in almost all the subgroup and sensitivity analyses. In conclusion, findings of the present meta-analysis suggested a lack of association between total dietary fat intake and EC risk. Further studies, especially prospective designed studies are warranted to confirm our findings.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26568366 PMCID: PMC4645223 DOI: 10.1038/srep16693
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Flow-chart of study selection.
Characteristics of studies included in the meta-analysis.
| First author (ref), year, Country | No. of cases/cohort, age, follow-up | Energy-adjusted model (unit) | Exposure categories (Dietary assessment) | Risk estimates (95% CI) | Matched/adjusted factors |
|---|---|---|---|---|---|
| Prospective study | |||||
| Merritt | 1303/301,107 (25–70y), 11y | Residual (g/day) | Quartile 4 | Hazard ratio 0.84 (0.71–0.99) 1.00 (0.82–1.23) 0.94 (0.80–1.11) | BMI, total energy intake, smoking status, age at menarche, OC use, parity, and a combined variable for menopausal status and postmenopausal hormone use and were stratified by age and study center |
| Merritt | 1531/155,406 (30–55y), 25y | Residual (g/day) | Quartile 4 | Hazard ratio 0.95 (0.81–1.11) | BMI, total energy intake, smoking status, age at menarche, OC use, parity, and menopausal status and postmenopausal hormone use and were stratified by age, cohort, and the 2-year questionnaire cycle |
| Cui | 669/68,070 (30–55y), 21y | N/A (g/day) | Quintile 5 | Relative Risk 0.84 (0.65–1.08) 0.99 (0.77–1.26) | Age, follow-up period, total energy, smoking, OC use, postmenopausal hormone use, age at menopause, parity, age at menarche, hypertension, diabetes, BMI |
| Furberg | 130/24,460 (20–49), 15.7y | N/A (g/day) | Per 19.4g/day Total fat (Validated FFQ) | Relative Risk 0.99 (0.82–1.20) | Age |
| Jain | 221/56,837 (40–59y), 9y | Residual (g/day) | Quartile 4 | Relative Risk 0.84 (0.58–1.23) 1.32 (0.90–1.93) 0.60 (0.40–0.90) | Total energy, age, BMI, ever smoked, used OC, used HRT, university education, livebirths, age at menarche |
| Zheng | 216/23,000 (55–69y), 7y | Residual (g/day) | Quintile 5 | Relative Risk 0.90 (0.50–1.60) 1.00 (0.50–1.80) | Age, age at menopause, post-menopausal hormone use, and total energy intake |
| Case-control study Biel | 506/981 (mean, 58.7/58.3y) | Residual (g/day) | Quartile 4 | Odds Ratio 1.12 (0.80–1.55) | Age, total energy intake, age at menarche, BMI, parity, educational level, hypertension history, OC use, HRT use combined with menopausal status, and alcohol consumption |
| Yeh | 541/541 (mean, 63.3/63.2y) | N/A (g/day) | Quartile 4 | Odds Ratio 1.21 (0.67–2.21) | Age, BMI, exogenous estrogen use, smoking, total menstrual months, total energy, total protein and carbohydrates intake |
| Lucenteforte | 454/908 (median, 60/61y) | Residual (g/day) | Quintile 5 | Odds Ratio 1.10 (0.70–1.60) | Age, study centre, year of interview, education, PA, BMI, history of diabetes, age at menarche, age at menopause, parity, OC use, HRT use, total energy intake, according to the residual models |
| Xu | 1204/1212 (mean, 54.5/54.6y) | Presented (g/1000 kcal/d) | Quintile 5 | Odds Ratio 1.10 (0.90–1.50) 0.60 (0.50–0.80) 1.50 (1.20–2.00) | Age, education, menopausal status, diagnosis of diabetes, alcohol consumption, PA, BMI, and total energy intake |
| Salazar-Martinez | 85/629 (mean, 51.7/57.1y) | Residual (g/day) | Tertile 3 | Odds Ratio 1.45 (0.61–3.44) 1.50 (0.68–3.32) 1.19 (0.55–2.58) | Age, total energy intake, number of live births, BMI, PA, and diabetes |
| McCann | 232/639 (mean, 63.5/55.9y) | N/A (g/day) | Quartile 4 | Odds Ratio 1.60 (0.70–3.40) | Age, education, BMI, diabetes, hypertension, pack-years cigarette smoking, age at menarche, parity, OC use, menopause status, postmenopausal estrogen use, and total energy intake |
| Jain | 552/562 (30–79y) | Residual (g/day) | Quartile 4 | Odds Ratio 1.21 (0.84–1.83) 1.66 (1.15–2.40) | Total energy, age, body weight, ever smoked, history of diabetes, used OC, used HRT, university education, live births, age at menarche |
| Tzonou | 145/298 (N/A) | N/A (g/day) | Quartile 4 | Odds Ratio 0.72 (0.42–1.25) | Age |
| Barbone | 168/334 (mean, 64/63y) | Residual (g/day) | Tertile 3 | Odds Ratio 0.60 (0.30–1.10) 1.30 (0.70–2.60) | Age, race, years of schooling, total calories, use of unopposed estrogens, obesity, shape of obesity, smoking, age at menarche, age at menopause, number of pregnancies, diabetes, and hypertension |
| Shu | 268/268 (mean, 56/56.4y) | N/A (g/day) | Quartile 4 | Odds Ratio 1.20 (0.70–1.90) 3.50 (2.00–6.00) | Age, number of pregnancies, BMI, and animal fat (for plant fat) |
BMI, body mass index; CI, confidence interval; HC-CS, hospital-based case-control study; PA, physical activity; PC-CS, population-based case-control study; N/A, not available; OC, oral contraceptive; FFQ, food frequency questionnaire.
*Risk estimates were calculated from published data with EpiCalc 2000 software (version 1.02; Brixton Health).
Methodological quality of prospective studies included in the meta-analysis*.
| First author (reference), publication year | Representativeness of the exposed cohort | Selection of the unexposed cohort | Ascertainment of exposure | Outcome of interest not present at start of study | Control for important factor or additional factor | Assessment of outcome | Follow-up long enough for outcomes to occur | Adequacy of follow-up of cohorts | Using an energy-adjusted model |
|---|---|---|---|---|---|---|---|---|---|
| Merritt | |||||||||
| Merritt | |||||||||
| Cui | – | ||||||||
| Furberg | – | – | |||||||
| Jain | – | ||||||||
| Zheng | – |
*A study could be awarded a maximum of one star for each item except for the item Control for important factor or additional factor. The definition/explanation of each column of the Newcastle-Ottawa Scale is available from (http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp).
†A maximum of 2 stars could be awarded for this item. Studies that controlled for total energy intake received one star, whereas studies that controlled for other important confounders such as body mass index, reproductive factors received an additional star.
‡A cohort study with a follow-up time >10 y was assigned one star.
§A cohort study with a follow-up rate >75% was assigned one star.
Methodological quality of case-control studies included in the meta-analysis*.
| First author (reference), publication year | Adequate definition of cases | Representativeness of cases | Selection of control subjects | Definition of control subjects | Control for important factor or additional factor | Exposure assessment | Same method of ascertainment for all subjects | Non response Rate | Using an energy-adjusted model |
|---|---|---|---|---|---|---|---|---|---|
| Biel | – | ||||||||
| Yeh | – | – | – | – | |||||
| Lucenteforte | – | – | |||||||
| Xu | – | ||||||||
| Salazar-Martinez | – | – | |||||||
| McCann | – | ||||||||
| Jain | – | ||||||||
| Tzonou | – | – | – | – | |||||
| Barbone | – | – | – | ||||||
| Shu | – | – | – |
*A study could be awarded a maximum of one star for each item except for the item Control for important factor or additional factor. The definition/explanation of each column of the Newcastle-Ottawa Scale is available from (http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp).
§One star was assigned if the control subjects were population-based.
†A maximum of 2 stars could be awarded for this item. Studies that controlled for total energy intake received one star, whereas studies that controlled for other important confounders such as body mass index, reproductive factors received an additional star.
‡One star was assigned if there was no significant difference in the response rate between control subjects and cases by using the chi-square test (P > 0.05).
Summary risk estimates of the association between dietary fat intake and endometrial cancer risk, dose-response analysis (per 30 g/day increment).
| No. of study | Summary RR (95%CI) | ||||
|---|---|---|---|---|---|
| Total dietary fat | 11 | 0.97 (0.94–1.001) | 0 | 0.44 | |
| Plant-based fat | 5 | 1.05 (0.94–1.18) | 0 | 0.63 | |
| Animal-based fat | 6 | 1.17 (0.92–1.36) | 85.0 | <0.01 | |
| Subgroup analyses of total dietary fat | |||||
| Study design | 0.13 | ||||
| Cohort study | 4 | 0.95 (0.91–0.98) | 0 | 0.85 | |
| Case-control study | 7 | 1.01 (0.96–1.06) | 0 | 0.63 | |
| Type of control subjects | 0.30 | ||||
| Population-based | 3 | 1.05 (0.97–1.13) | 0 | 0.95 | |
| Hospital-based | 4 | 0.99 (0.93–1.05) | 0 | 0.41 | |
| Geographic location | 0.31 | ||||
| North America | 7 | 0.99 (0.95–1.04) | 25.7 | 0.23 | |
| Europe | 4 | 0.95 (0.91–0.99) | 0 | 0.88 | |
| Validated FFQ | 0.61 | ||||
| Yes | 10 | 0.97 (0.94–1.01) | 7.6 | 0.37 | |
| No | 1 | 0.95 (0.87–1.03) | N/A | N/A | |
| Number of cases | 0.67 | ||||
| ≥500 | 5 | 0.98 (0.94–1.03) | 35.5 | 0.19 | |
| <500 | 6 | 0.96 (0.91–1.01) | 0 | 0.61 | |
| Energy-adjusted model | 0.51 | ||||
| Yes | 7 | 0.97 (0.93–1.01) | 15.6 | 0.31 | |
| No | 4 | 0.99 (0.93–1.06) | 0 | 0.50 | |
| Adjustment for potential confounders | |||||
| Total energy intake | 0.63 | ||||
| Yes | 9 | 0.98 (0.94–1.01) | 17.8 | 0.28 | |
| No | 2 | 0.95 (0.88–1.03) | 0 | 0.84 | |
| Body mass index | 0.63 | ||||
| Yes | 9 | 0.98 (0.94–1.01) | 17.8 | 0.28 | |
| No | 2 | 0.95 (0.88–1.03) | 0 | 0.84 | |
| Cigarette smoking | 0.94 | ||||
| Yes | 7 | 0.98 (0.94–1.02) | 28.6 | 0.21 | |
| No | 4 | 0.97 (0.91–1.04) | 0 | 0.67 | |
| Parity | 0.63 | ||||
| Yes | 9 | 0.98 (0.94–1.01) | 17.8 | 0.28 | |
| No | 2 | 0.95 (0.88–1.03) | 0 | 0.84 | |
| Oral contraceptive use | 0.62 | ||||
| Yes | 7 | 0.97 (0.93–1.00) | 12.1 | 0.34 | |
| No | 4 | 0.99 (0.92–1.06) | 0 | 0.42 | |
| Menopausal status | 0.70 | ||||
| Yes | 6 | 0.97 (0.94–1.01) | 7.7 | 0.37 | |
| No | 5 | 0.96 (0.91–1.02) | 9.3 | 0.35 | |
| Hormone replacement therapy use | 0.86 | ||||
| Yes | 8 | 0.98 (0.94–1.01) | 18.5 | 0.28 | |
| No | 3 | 0.96 (0.89–1.04) | 0 | 0.51 | |
CI, confidence interval; N/A, not available; RR, relative risk.
*P-value for heterogeneity within each subgroup.
**P-value for heterogeneity between subgroups with meta-regression analysis in random-effect model.
Figure 2Forest plots (random effect model) of meta-analysis on the relationship between total dietary fat intake and endometrial cancer risk by study design.
Squares indicate study-specific risk estimates (size of the square reflects the study-specific statistical weight); horizontal lines indicate 95% CIs; diamond indicates the summary relative risk with its 95% CI. RR: relative risk.
Figure 3Forest plots (random effect model) of meta-analysis on the relationship between total dietary fat intake and endometrial cancer risk by the source of fat.
Squares indicate study-specific risk estimates (size of the square reflects the study-specific statistical weight); horizontal lines indicate 95% CIs; diamond indicates the summary relative risk with its 95% CI. RR: relative risk.